Organization
Nykode Therapeutics
6 clinical trials
63 abstracts
Clinical trial
A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients With Advanced or Recurrent, Non-resectable HPV 16-Positive Cervical CancerStatus: Completed, Estimated PCD: 2023-11-24
Clinical trial
A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 and Pembrolizumab in Patients With Unresectable Recurrent or Metastatic HPV16-positive Head-Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2022-12-16
Clinical trial
An Open Labelled First Human Dose Phase 1/2a Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With Individualised VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Clear Renal Cell Carcinoma, Urothelial Cancer or Squamous Cell Carcinoma of Head and Neck, Who Did Not Reach Complete Responses With Current Standard of Care Immune Checkpoint BlockadeStatus: Completed, Estimated PCD: 2023-01-30
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Integrating polygenic risk scores into clinical breast cancer models: Influence on prediction in diverse cohorts.Org: Allelica Inc, Rome, Nykode Therapeutics, Hartford Healthcare Cancer Institute, Italy,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,
Abstract
Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2- metastatic breast cancer (mBC) in the US.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, PLC, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Racial disparities among triple negative breast cancer clinical trial enrollees between 2010-2023.Org: New York Medical College, Valhalla, Nykode Therapeutics, Albert Einstein College of Medicine, Bronx, NY,
Abstract
Memory mayhem: Hormone therapy causing brain fog in patients with DCIS.Org: SUNY Upstate Medical University, Syracuse, NY, Nykode Therapeutics, SUNY Upstate University Hospital, SUNY Upstate Medical Center,
Abstract
Characteristics and pregnancy outcomes of pregnant women by cancer diagnosis status.Org: Komodo Health, San Francisco Medical Center, CanSino Biologics, New York City, Nykode Therapeutics,
Abstract
Examining 1-year mortality risk among patients with malignant melanoma undergoing immune checkpoint inhibitor therapy with a history of cannabis use.Org: Fairfield Medical Center, Lancaster, OHB Neonatology, West Virginia University School of Medicine, Morgantown,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).Org: Cancer Center, Stanford, Palo Alto, CA, Foundation Medicine, Inc., San Diego, CA, Foundation Medicine, Inc., Cambridge, MA, SUNY Upstate Medical University, Syracuse, NY, Foundation Medicine, Inc., Boston, MA,
Abstract
Improving adequacy rates of bone marrow aspirate and core biopsies through training and a bedside X-ray device.Org: Westchester Medical Center, Valhalla, NY, Nykode Therapeutics,
Abstract
Characterization of cancer clinical trials in the community setting.Org: Flatiron Health, San Francisco, CA, New York Oncology Hematology PC, Nykode Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA,
Abstract
Disparities in cancer care: Is there a benefit for increased use of inpatient chemotherapy (IPC) in safety-net hospitals?Org: Jacobi Medical Center/North Central Bronx, Bronx, NY, Nykode Therapeutics, Albert Einstein College of Medicine,
Abstract
Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Center for Molecular Oncology,
Abstract
Risk of stroke in patients with atrial fibrillation and chronic lymphocytic leukemia.Org: Northwell Staten Island University Hospital, New York Oncology Hematology PC, Nykode Therapeutics, Staten Island University Hospital, Northwell Health, New Hyde Park, NY,
Abstract
Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Org: Memorial Sloan Kettering Cancer Center, New York City, Nykode Therapeutics, New York Oncology Hematology PC, Columbia University Vagelos College of Physicians and Surgeons,
Abstract
Impact of hyponatremia on multiple myeloma hospitalizations: A nationwide analysis.Org: Brooklyn Hospital Center, Brooklyn, NY, Brooklyn ImmunoTherapeutics, Nykode Therapeutics, The Brooklyn Hospital Center, New York, NY, New York Oncology Hematology PC,
Abstract
Anticoagulation and lung cancer mortality: A National Inpatient Sample analysis 2020.Org: Jacobi Medical Center/North Central Bronx, NYC Health and Hospitals, Bronx, NY, Nykode Therapeutics, Northwell Health, New Hyde Park, NY,
Abstract
Reasons for biomarker testing in NSCLC: An analysis of reasoning between 2021-2023 in early- vs. late-stage patients.Org: Ipsos, New York Oncology Hematology PC, Nykode Therapeutics, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,
Abstract
Surgical decision-making after neoadjuvant chemotherapy for breast cancer.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York Oncology Hematology PC, Nykode Therapeutics,
Abstract
Navigating the intersection: Exploring racial disparities in major cardiovascular and cerebrovascular events among patients with hepatocellular carcinoma.Org: Landmark Medical Center, Woonsocket, River 3 Renal, New York Medical College - Saint Michael's Medical Center, Valhalla,
Abstract
Epidemiological trends and socioeconomic factors in malignant peripheral nerve sheath tumors with rhabdomyoblastic differentiation: A National Cancer Database study.Org: Creighton University School of Medicine-Phoenix, Phoenix Tissue Repair, Azidus Brasil, Creighton SOM, Brandeis University,
Abstract
How febrile neutropenia affects hospitalization in patients with bladder cancer: Nationwide insights.Org: University of Missouri-Columbia, School of Medicine, Zhejiang University, Hangzhou, China, Columbia University - Mailman School of Public Health, ModernaTX, Wyckoff Heights Medical Center,
Abstract
Trial eligibility criteria (EC) and diversity among patients with advanced non small cell lung cancer (advNSCLC).Org: Flatiron Health, San Francisco, CA, New York Oncology Hematology PC, Nykode Therapeutics, Flatiron Health, Inc.,
Abstract
Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis.Org: King Edward Medical University, Lahore Medical Research Center, Pakistan, King Edward Medical University Pakistan, Jhelum,
Abstract
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.Org: University of Texas MD Anderson Cancer Center, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Txinno Bioscience, University of Virginia, Charlottesville, VA, USA, Charlottesville, VA,
Abstract
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,
Abstract
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.Org: Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, Pfizer,
Abstract
Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Lake Erie College of Osteopathic Medicine,
Abstract
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,
Abstract
Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma: A phase II trial.Org: McGill University Health Center, Montréal, QC, Canada, QC Kinetix, Canada's Michael Smith Genome Sciences Centre, Research Institute of McGill University Health Centre,
Abstract
Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).Org: University of Pennsylvania, Philadelphia, PA, PainReform, CVS Health, Perelman School of Medicine,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?Org: Weill Cornell Medicine - Qatar, Doha, Qatar, Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Racial and ethnic disparities in survival among persons with subsequent primary cancer.Org: American Cancer Society, Atlanta Cancer Care, Galderma R&D, Kennesaw, GA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.Org: City of Hope National Comprehensive Cancer Center, Duarte, CA, CanSino Biologics, SWOG Statistics and Data Management Center, Seattle, WA, Seattle Gummy Company,
Abstract
Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints.Org: University of California San Diego, Moores Cancer Center, UC San Diego Health, La Jolla, CA, CanSino Biologics, Children's Oncology Group,
Abstract
Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.Org: American Cancer Society, Atlanta Cancer Care, Galderma R&D, Emory University School of Medicine, Roswell Park Comprehensive Cancer Center,
Abstract
AI-driven real-time patient identification for randomized controlled trials.Org: Mango Sciences, Inc., Boston Pharmaceuticals, Subhash Nagar, Nelamangala, Indiana University – Purdue University Indianapolis,
Abstract
Real-world behavioral restrictional practices of cancer patients (pts).Org: Sourasky Medical Center, Tel Aviv, Israel, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical center, Tel Aviv, Israel, Tel Aviv-Yafo, Israeli Medical Research Center, Research Unit “Dr. Mirko Grmek,” Psychiatric Clinic “Sveti Ivan”,
Abstract
A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Nykode Therapeutics, Cornell University, Morehouse School of Medicine,
Abstract
Carcinoid tumor of the bronchus and lung: A nationwide cross-sectional study.Org: St. Barnabas Hospital, Bronx, NY, Nykode Therapeutics,
Abstract
Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC.Org: Piedmont Cancer Institue, Atlanta Cancer Care, Galderma R&D, BeyondSpring Pharmaceuticals, Inc., NewYork-Presbyterian Brooklyn Methodist Hospital,
Abstract
Real-world treatment patterns of non-small cell lung cancer in an Indian hospital.Org: Mango Sciences, Inc., Boston Pharmaceuticals, MaaT Pharma, Subhash Nagar, Nelamangala,
Abstract
In-hospital outcomes of patients with breast cancer and venous thromboembolism.Org: St Vincent Hospital, Worcester HIV Vaccine, MaaT Pharma, Brooklyn Hospital Program, Brooklyn ImmunoTherapeutics,
Abstract
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.Org: University of Linköping, Linköping University Hospital, Sweden, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences,
Abstract
Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes.Org: Sheba Medical Center, Or-Yeuda, Ramat Gan, Israel, Israeli Medical Research Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice,
Abstract
The impact of COVID-19 on patient involvement in treatment decisions in the US and EU4+UK.Org: Ipsos Insight, Kuala Lumpur, Malaysia, Malaysia, New York Oncology Hematology PC, Nykode Therapeutics,
Abstract
Targeting HE4 for treatment of endometrial cancer using a novel small molecule inhibitor.Org: University of Rochester Medical School, Rochester Regional Health System, Nykode Therapeutics,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Effect of TFF2-MSA on tumor growth and survival in anti-PD-1 treated MC38 and CT26.wt colorectal cancer models by targeting MDSCs.Org: Tonix Pharmaceuticals, Chatham, NJ, Southern Research Institute, Birmingham, AL,
Abstract
Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.Org: University of Iowa Hospitals & Clinics, Iowa City VA Medical Center, Pfizer, New York Oncology Hematology PC, Nykode Therapeutics,
Abstract
Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,
Abstract
Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, Nykode Therapeutics, New York University School of Medicine,
Abstract
Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC.Org: Montefiore-Einstein Cancer Center, The Bronx, NY, Nykode Therapeutics, Albert Einstein College of Medicine, Bronx, NY,
Abstract
Addressing the clinical trial selection process to improve representation by African American patients with breast cancer in cancer clinical trials.Org: Loyola University Medical Center, Maywood, IL, Il-Yang Pharmaceuticals, University of Rochester Medical School, Rochester Regional Health System,